Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Faiyaaz Kalimullah

Dermatology Chicago, IL Medical Doctor

NPI 1063729895 CMS profile 48247

755 N Wells St, Suite 201, Chicago, IL 60654

Open in the dashboard

General payments

$137,120

819 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Faiyaaz Kalimullah of Chicago, IL is reported in the CMS Open Payments database as having received $137,120 across 819 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,157 134
2024 General $11,310 122
2023 General $36,830 172
2022 General $25,569 107
2021 General $38,078 124
2020 General $12,895 66
2019 General $5,281 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Faiyaaz Kalimullah
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Faiyaaz Kalimullah were reported at $7,157. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Faiyaaz Kalimullah Dermatology median Middle half National median
2019 $5,281 $454 $129–$1,240 $163
2020 $12,895 $235 $81–$756 $114
2021 $38,078 $377 $108–$1,108 $132
2022 $25,569 $514 $143–$1,391 $149
2023 $36,830 $607 $159–$1,674 $160
2024 $11,310 $751 $204–$1,903 $164
2025 $7,157 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $63,851 110 payments
  2. AbbVie, Inc. $50,108 183 payments
  3. Galderma Laboratories, L.P. $13,874 80 payments
  4. Janssen Biotech, Inc. $1,443 84 payments
  5. Pfizer Inc. $1,004 37 payments
  6. Regeneron Healthcare Solutions, Inc. $980 40 payments
  7. Amgen Inc. $823 37 payments
  8. Lilly USA, LLC $751 37 payments
  9. Revance Therapeutics, Inc. $481 4 payments
  10. Dermavant Sciences, Inc. $439 36 payments
  11. Other $3,366 171 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $107,258 95 payments
  2. Food and Beverage $18,041 683 payments
  3. Consulting Fee $7,800 1 payment
  4. Travel and Lodging $3,709 36 payments
  5. Education $312 4 payments
Products named General payments · program years 2019–2025
  1. BOTOX $41,690 84 payments
  2. SOOLANTRA $12,341 30 payments
  3. BOTOX COSMETIC $2,798 8 payments
  4. KYBELLA $1,950 1 payment
  5. ORACEA $1,488 24 payments
  6. TREMFYA $1,265 75 payments
  7. SKYRIZI $887 37 payments
  8. Otezla $823 37 payments
  9. EUCRISA $808 29 payments
  10. DUPIXENT $774 33 payments
  11. Other $9,952 461 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$2,993

Medicare's payments for the services billed

Medicare patients

15

Average age 72

Services billed

36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
$4,750 — —
TREMFYA
$296 — —
VTAMA
$216 — —
DAXXIFY
$179 — —
RINVOQ
$144 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

819 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record